Multifaceted roles of APOE in Alzheimer disease
Nature Reviews Neurology · 2024-08 · 20 (8) · 457-474
DOI: 10.1038/s41582-024-00988-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Neurology, online erschienen am 21.06.2024. Verfasst von Rosemary J Jackson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Apolipoproteins E. Die Arbeit wurde bisher 215-mal zitiert (Crossref) und nennt 277 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
For the past three decades, apolipoprotein E (APOE) has been known as the single greatest genetic modulator of sporadic Alzheimer disease (AD) risk, influencing both the average age of onset and the lifetime risk of developing AD. The APOEε4 allele significantly increases AD risk, whereas the ε2 allele is protective relative to the most common ε3 allele. However, large differences in effect size exist across ethnoracial groups that are likely to depend on both global genetic ancestry and local genetic ancestry, as well as gene-environment interactions. Although early studies linked APOE to amyloid-β - one of the two culprit aggregation-prone proteins that define AD - in the past decade, mounting work has associated APOE with other neurodegenerative proteinopathies and broader ageing-related brain changes, such as neuroinflammation, energy metabolism failure, loss of myelin integrity and increased blood-brain barrier permeability, with potential implications for longevity and resilience to pathological protein aggregates. Novel mouse models and other technological advances have also enabled a number of therapeutic approaches aimed at either attenuating the APOEε4-linked increased AD risk or enhancing the APOEε2-linked AD protection. This Review summarizes this progress and highlights areas for future research towards the development of APOE-directed therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. bhyman@mgh.harvard.edu.
- Harvard Medical School, Boston, MA, USA. bhyman@mgh.harvard.edu.
- Massachusetts Alzheimer's Disease Research Center, Charlestown, MA, USA. bhyman@mgh.harvard.edu.
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. aserrano1@mgh.harvard.edu.
ORCID-Profile: Bradley T Hyman, Alberto Serrano-Pozo
Förderung
- NIA NIH HHS
- NINDS NIH HHS
Zitieren
APA
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024). Multifaceted roles of APOE in Alzheimer disease. Nature Reviews Neurology, 20(8), 457-474. https://doi.org/10.1038/s41582-024-00988-2
Vancouver
Jackson RJ, Hyman BT, Serrano-Pozo A. Multifaceted roles of APOE in Alzheimer disease. Nature Reviews Neurology. 2024;20(8):457-474. doi:10.1038/s41582-024-00988-2
BibTeX
@article{Jackson2024,
author = {Jackson, Rosemary J and Hyman, Bradley T and Serrano-Pozo, Alberto},
title = {Multifaceted roles of APOE in Alzheimer disease},
journal = {Nature Reviews Neurology},
year = {2024},
volume = {20},
number = {8},
pages = {457--474},
doi = {10.1038/s41582-024-00988-2}
}
EUVIMED